123 related articles for article (PubMed ID: 31058459)
1. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459
[TBL] [Abstract][Full Text] [Related]
2. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro.
Lin QM; Li YH; Lu XR; Wang R; Pang NH; Xu RA; Cai JP; Hu GX
Chem Res Toxicol; 2019 Aug; 32(8):1583-1590. PubMed ID: 31293154
[TBL] [Abstract][Full Text] [Related]
4. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
[TBL] [Abstract][Full Text] [Related]
5. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
[TBL] [Abstract][Full Text] [Related]
6. Functional assessment of
Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro.
Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L
Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC; Zheng X; Liu TH; Wang CC; Tang PF; Chen Z; Zhang BW; Fang P; Hu GX; Cai JP
Xenobiotica; 2019 Jan; 49(1):120-126. PubMed ID: 29394111
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro.
Li YH; Lu XR; Lin QM; Huang HL; Liang XL; Cai JP; Cui J; Hu GX
J Pharm Pharmacol; 2019 Nov; 71(11):1677-1683. PubMed ID: 31441067
[TBL] [Abstract][Full Text] [Related]
11. Metabolic profiling of the anti-tumor drug regorafenib in mice.
Wang YK; Xiao XR; Xu KP; Li F
J Pharm Biomed Anal; 2018 Sep; 159():524-535. PubMed ID: 30055476
[TBL] [Abstract][Full Text] [Related]
12. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B; Zhang XD; Wen J; Zhang B; Chen D; Wang S; Cai JP; Hu GX
Chem Res Toxicol; 2020 Jan; 33(1):172-180. PubMed ID: 31560202
[TBL] [Abstract][Full Text] [Related]
13. Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism.
Yuan LJ; Li XY; Ni JH; Wang J; Xu XY; Luo JC; Zhou Q; Hu GX; Cai JP; Qian JC
Toxicol Appl Pharmacol; 2023 Sep; 475():116653. PubMed ID: 37574146
[TBL] [Abstract][Full Text] [Related]
14. Functional Analysis of Wild-Type and 27 CYP3A4 Variants on Dronedarone Metabolism
Wang CC; Lan T
Curr Drug Metab; 2022; 23(7):562-570. PubMed ID: 35702776
[TBL] [Abstract][Full Text] [Related]
15. Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q; Ou-Yang QG; Lin QM; Lu XR; Ma YQ; Li YH; Xu RA; Lin DD; Hu GX; Cai JP
Fundam Clin Pharmacol; 2022 Feb; 36(1):150-159. PubMed ID: 33961299
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel substrates for human cytochrome P450 2J2.
Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
[TBL] [Abstract][Full Text] [Related]
17. Identification and Functional Assessment of Eight
Qi Y; Yang H; Wang S; Zou L; Zhao F; Zhang Q; Hong Y; Luo Q; Zhou Q; Geng P; Chen H; Ji F; Cai J; Dai D
Drug Metab Dispos; 2024 Feb; 52(3):218-227. PubMed ID: 38195522
[TBL] [Abstract][Full Text] [Related]
18. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
19. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
[TBL] [Abstract][Full Text] [Related]
20. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
